Home | | | Search | | | Browse | | | Resources | | | Help | | | What's New | | | About |
---|
L-glutamine Therapy for Sickle Cell Anemia
This study is currently recruiting patients.
Sponsored by: | FDA Office of Orphan Products Development |
---|---|
Information provided by: | FDA Office of Orphan Products Development |
Purpose
This is a study to determine the efficacy of L-glutamine as therapy for sickle cell anemia and sickle O-thalassemia.
Condition | Treatment or Intervention | Phase |
---|---|---|
Anemia, Sickle Cell Thalassemia |
Drug: L-glutamine |
Phase II Phase III |
MedlinePlus related topics: Anemia; Sickle Cell Anemia
Genetics Home Reference related topics: sickle cell anemia
Study Type: Interventional
Study Design: Treatment, Randomized, Double-Blind, Placebo Control, Crossover Assignment, Efficacy Study
Expected Total Enrollment: 80
Study start: September 2001;
Study completion: September 2004
Sickle cell anemia is one of the most common and devastating hereditary disorders with significant morbidity and mortality affecting individuals of African-American heritage. No safe effective therapy is yet available. An ideal agent would be one that is readily available, effective, and safe even with chronic use. Early studies using L-glutamine in a few patients show promising results. This is an amino acid that has been used widely for other purposes and shown to be safe.
Patients are assigned randomly to receive L-glutamine or placebo orally 3 times a day for 24 weeks after which patients will cross over to the other treatment arm for 24 weeks. Clinical parameters, adverse effects attributable to L-glutamine, and physiological parameters will be monitored throughout the study.
Eligibility
Ages Eligible for Study: 5 Years and above, Genders Eligible for Study: Both
Criteria
Inclusion criteria:
Exclusion criteria:
Location and Contact Information
More Information
U.S. National Library of Medicine, Contact NLM Customer Service | ||||||||||||||
National Institutes of Health, Department of Health & Human Services | ||||||||||||||
Copyright, Privacy, Accessibility, Freedom of Information Act |